According to reports, Cantor Fitzgerald CEO Howard Lutnick is now in the running to become President-elect Trump's Treasury ...

Two prominent supporters of President-elect Trump’s campaign have emerged as the frontrunners to lead the Treasury Department ...

(Reuters) -Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a ...

President-elect Donald Trump's picks for US attorney general and secretary of state illustrate a potential hardline approach ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 1.73% of ...

Cantor Fitzgerald CEO and President-elect Donald Trump’s transition co-chair, Howard Lutnick, is said to be "campaigning hard ...

Small caps’ (NYSEARCA:IWM), (SP600) outperformance should continue into the year-end, according to Eric Johnston, senior ...

As Bitcoin soars to record highs, cryptocurrency executives are maneuvering to influence Donald J. Trump’s transition and ...

On Tuesday, a tiny shred of data on Amgen’s lead obesity candidate — not yet verified — erased $12 billion in market value.

Cantor Fitzgerald tells investors that MariTide’s Phase 1 data includes “a big surprise” as the supplemental appendix file ...

Amgen (NASDAQ:AMGN) shares fell in the evening hours on Tuesday after Cantor Fitzgerald argued that a potential loss of bone ...